摘要
目的：探讨人尿激肽原酶治疗急性缺血性脑卒中的效果，为急性缺血性脑卒中的治疗提供依据。方法选取2011年12月-2013年12月辽宁省盘锦市中心医院收治的急性缺血性脑卒中患者120例作为研究对象，分为两组，各60例。对照组根据病情合理选用甘露醇脱水降颅压、阿司匹林抗血小板聚集、防治并发症、必要的营养支持和康复治疗等常规治疗；治疗组在此基础上用人尿激肽原酶0.15PNAu加入生理盐水250mL中静脉滴注，每天1次，连用14 d。观察两组患者治疗效果、治疗前后神经功能缺损评分（NIHSS），以及治疗后日常生活能力情况、复发及不良反应情况。结果治疗组基本治愈17例，显著进步31例，进步10例，无效2例，恶化0例，总有效率为96.67%；对照组基本治愈12例，显著进步21例，进步8例，无效16例，恶化3例，总有效率为68.33%；两组总有效率相比，差异有统计学意义（P〈0.05）；治疗组治疗14 d后NIHSS评分[（7.06±3.64）分]显著优于治疗前[（15.03±5.77）分]和对照组治疗后[（9.85±4.35）分]，差异均有统计学意义（P〈0.05）；治疗组治疗后日常生活活动能力评分[（58.4±5.6）分]显著优于治疗前[（38.7±6.3）分]和对照组治疗后[（43.3±5.4）分]，差异均有统计学意义（P〈0.05）；治疗组治疗14d后hs-CRP水平[（2.13±0.30）mol/L]显著低于治疗前[（6.73±0.78）mol/L]和对照组治疗后[（3.73±0.43）mol/L]，差异有统计学意义（P〈0.05）；两组患者治疗期间均无严重不良反应发生。结论应用人尿激肽原酶能够显著改善急性缺血性脑卒中患者神经功能缺损程度，提高患者后期的生活能力，降低血清hs-CRP水平，减轻炎性反应，有良好的临床疗效，值得临床推广应用。
Objective To evaluate the effects of human urinary kallidinogenase in the treatment of acute cerebral in-farction, in order to provide a better way for acute cerebral infarction treatment. Methods 120 patients with acute cere-bral infarction from December 2011 to December 2013 in the Central Hospital of Panjin City were selected and divided into two groups, each group had 60 cases. Patients in the control group were given treatment including reasonable selection of mannitol for reducing intracranial pressure, Aspirin for anti-platelet aggregation, prevention of complications, necessary nutritional support, rehabilitation therapy and other conventional treatment. Patients in the treatment group were given urinary kallidinogenase 0.15 PNAu joined in 250 mL of normal saline intravenously once a day for 14 d, on the basis of the control group. The treatment efficacy, neurological deficit score （NIHSS） before and after treatment, live ability after treatment, the recurrence and adverse reactions after treatment were observed in the two groups. Results In the treatment group 17 cases had cured, 31 cases had significant progress, 10 cases had progress, 2 cases had invalid, no one had deteriorate, the total effective rate was 96.67%; while in the control group, there were 12, 21, 8, 16 and 3 cases retrospectively, the total effective rate was 68.33%; the difference between the two groups in the total effective rate was statistically significant （P〈0.05）. After 14 days of treatment, NIHSS score [（7.06±3.64） scores] in the treatment group was significantly lower than that of before treatment [（15.03±5.77） scores] and the control group after treatment [（9.85±4.35） scores], the differences were statistically significant （P〈0.05）. After treatment activities of daily living score in the treatment group [（58.4±5.6） scores] was significantly higher than that of before treatment [（38.7±6.3） scores] and the control group after treatment [（43.3±5.4） scores], the differences were statist
出处
《中国医药导报》
CAS
2014年第32期68-71,共4页
China Medical Herald
关键词
人尿激肽原酶
急性缺血性脑卒中
超敏C-反应蛋白
Human urinary kallidinogenase
Acute ischemic stroke
Ultra-sensitivity C-reactive protein
